Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
ERLEADA® (apalutamide) demonstrates statistically significant and clinically ...
ERLEADA® (apalutamide) showed a 23% reduction in death risk at 24 months compared to enzalutamide in metastatic castration-sensitive prostate cancer patients, according to a real-world study presented at the 6th European Congress of Oncology Pharmacy.
Related Clinical Trials:
Cilta-Cel Is Safe, Efficacious in Real-World Treatment of Myeloma
Real-world patients with relapsed/refractory multiple myeloma showed deep responses with ciltacabtagene autoleucel (cilta-cel), with an 89% objective response rate (ORR) and 70% complete response (CR) rate. Safety aligned with clinical trial data, and 12-month progression-free survival (PFS) rates were 68% overall, 72% in conforming cilta-cel recipients, and 73% in those with fludarabine/cyclophosphamide lymphodepletion. Despite over half not meeting trial eligibility criteria, cilta-cel demonstrated feasibility and durability in this population.
Eli Lilly, Johnson & Johnson Invest in New Drug Manufacturing Facilities
Eli Lilly invests $4.5 billion in Lilly Medicine Foundry in Indiana for advanced drug manufacturing, aiming to accelerate next-generation medicine delivery. Johnson & Johnson announces $2 billion investment in a biologics facility in North Carolina to support 70+ new therapies by 2030.
ERLEADA demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
ERLEADA showed a statistically significant overall survival benefit at 24 months compared to enzalutamide in metastatic castration-sensitive prostate cancer patients, according to a real-world study presented at the 6th European Congress of Oncology Pharmacy.
Related Clinical Trials:
As 2seventy Nears Breakeven, CEO Chip Baird Explains How the Team Survived
Despite numerous challenges, 2seventy bio, formerly part of bluebird bio, remains focused on achieving profitability with its CAR T therapy Abecma. The company has undergone layoffs, pipeline reorganizations, and faced competition and FDA safety warnings. CEO Chip Baird predicts profitability next year, with potential growth strategies including acquisitions or licensing deals. The company's culture and resilience among its employees have been key to its survival.
Fresenius Kabi and Formycon Announce Approval of Stelara® Biosimilar Otulfi™ in the U.S. and E.U.
FDA approved Fresenius Kabi and Formycon's Otulfi™ (ustekinumab-aauz) as the fourth biosimilar of Janssen/Johnson & Johnson’s Stelara® (ustekinumab) on September 27, 2024, following Amgen’s Wezlana™, Alvotech/Teva’s Selarsdi™, and Samsung Bioepis/Sandoz’s Pyzchiva®. Otulfi™ received EU approval on the same day. Under settlement agreements, Otulfi™, Wezlana™, Selarsdi™, and Pyzchiva® can enter the U.S. market by February 2025. Numerous Stelara® biosimilars await FDA approval, with no pending patent disputes.
Niemann-Pick disease: FDA approves first two drugs in the space of a week for rare disorder
The FDA approved two drugs, Miplyffa and Aqneursa, for treating Niemann-Pick disease type C within a week, offering the first treatments for this fatal disorder. Miplyffa, a combination therapy with Zavesca, demonstrated efficacy in halting disease progression, while Aqneursa, a standalone therapy, showed significant neurological improvements. Both companies launched support programs to aid patient access to these treatments.
J&J and Legend share long-term results for Carvykti in phase 3 multiple myeloma study
J&J and Legend Biotech report positive long-term results for Carvykti, a BCMA-directed T-cell immunotherapy for multiple myeloma, showing a 45% reduction in death risk compared to standard therapies after a median follow-up of almost three years.
Fresenius Kabi, Formycon secure FDA approval for Stelara biosimilar Otulfi
Fresenius Kabi and Formycon receive FDA approval for Otulfi, a biosimilar to J&J's Stelara, indicated for Crohn's disease, ulcerative colitis, moderate to severe plaque psoriasis, and active psoriatic arthritis. Otulfi is Fresenius Kabi's fourth biosimilar in the US, supported by comprehensive data showing comparable efficacy, safety, pharmacokinetics, and immunogenicity to Stelara.
Every Cure Announces Leaders in Drug Development Joining its Executive Team
Every Cure adds Richard Riese, MD, PhD, as Chief Medical Officer, and Ruxandra Draghia-Akli, MD, PhD, as Chair of the Scientific Advisory Board, to advance AI-driven drug repurposing for neglected diseases.
© Copyright 2024. All Rights Reserved by MedPath